Please enable JavaScript.
Coggle requires JavaScript to display documents.
BPH (Treatment (surgery (TURP (endoscopic resectoscope inserted through…
BPH
Treatment
-
-
-
-
Nonpharm
low fat diet
high intake of fresh fruits and veggies
physical exercise
no smoking
avoid excessive caffeine and alcohol
-
surgery
-
indicated for pt with moderate-to-severe sx, who are not responsive to or cannot tolerate adverse effects of drug therapy, who are noncompliant with drug therapy, or who prefer surgical intervention
TURP
endoscopic resectoscope inserted through the urethra is used to remove the inside core of the prostatic adenoma.
-
-
TUIP
in short term TUIP is as effective as TURP but requires less operation time, causes less blood loss, and produces fewer adverse effects
-
Monitoring
-
-
-
anticholinergic agents
mental status, bowel habits, ability to urinate
-
-
Pathophysiology/Etiology
Precise Pathophysiology of BPH is unclear
Role of DHT & type II 5alpha-reductase
A combo of static and dynamic factors
Static factors:
from anatomic enlargement of the prostate gland, produces a physical block at the bladder neck and obstructs urinary outflow
Enlargement of the gland depends on androgen stimulation (epithelial tissue) and estrogen stimulation (stromal tissue)
Dynamic factors: relate to excessive alpha-adrenergic tone of the stromal component of prostate
Contraction of the prostate gland around the urethra and narrowing of the urethral lumen
Medications contributing to the development of BPH & BPH-symptoms: testosterone replacement regimens, alpha-adrenergic agonists used as oral/intranasal decongestants, beta-adrenergic agonists, drugs with anticholinergic SE, diuretics
Clinical Presentation
Sx
Obstructive: slow urinary stream, intermittency, hesitancy, straining to urinate, incomplete emptying, dribbling
Irritative symptoms: urgency, frequency, nocturia
Signs
enlarge prostate (>20 g) with no nodules or indurations; prostate is soft, symmetric, and mobile
Labs
increased BUN and SCr, elevated PSA
Other diagnostic tests
Increased AUA symptom score, decreased urinary flow rate (<10 ml/s), and increased PVR urine volume
Goals of Therapy
control sx, as evidenced by a minimum of a three-point decrease in the AUA sx index, prevent BPH disease by reducing the risk of developing complications, and delay the need for surgical intervention